Factors Influencing Stent Failure in Chronic Total Occlusion Coronary Intervention

Author:

Mahadevan Kalaivani1ORCID,Cosgrove Claudia2ORCID,Strange Julian W1

Affiliation:

1. Department of Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

2. Department of Cardiology, St George’s University NHS Trust, London, UK

Abstract

Stent failure remains one of the greatest challenges for interventional cardiologists. Despite the evolution to superior second- and third-generation drug-eluting stent designs, increasing use of intracoronary imaging and the adoption of more potent antiplatelet regimens, registries continue to demonstrate a prevalence of stent failure or target lesion revascularisation of 15–20%. Predisposition to stent failure is consistent across both chronic total occlusion (CTO) and non-CTO populations and includes patient-, lesion- and procedure-related factors. However, histological and pathophysiological properties specific to CTOs, alongside complex strategies to treat these lesions, may potentially render percutaneous coronary interventions in this cohort more vulnerable to failure. Prevention requires recognition and mitigation of the precipitants of stent failure, optimisation of interventional techniques, including image-guided precision percutaneous coronary intervention, and aggressive modification of a patient’s cardiovascular risk factors. Management of stent failure in the CTO population is technically challenging and itself begets recurrence. We aim to provide a comprehensive review of factors influencing stent failure in the CTO population and strategies to attenuate these.

Publisher

Radcliffe Group Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference92 articles.

1. Bonaa K, Mannsverk J, Wiseth R, et al. Drug eluting or bare metal stents for coronary artery disease. N Engl J Med 2016;375:1242–52. https://doi.org/10.1056/NEJMoa1607991; PMID: 27572953.

2. Stolker JM, Cohen DJ, Kennedy KF, et al. Repeat revascularisation after contemporary percutaneous coronary intervention; an evaluation of staged, target lesion and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv 2012;5:772–82. https://doi.org/10.1161/CIRCINTERVENTIONS.111.967802; PMID: 23093553.

3. Kandzari DE, Leon MB, Meredith I, et al. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc Interv 2013;6:504–12. https://doi.org/10.1016/j.jcin.2012.12.125; PMID: 23602459.

4. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606–13. https://doi.org/10.1093/eurheartj/ehr479; PMID: 22232428.

5. Navarese EP, Kowalewski M, Kandzari D, et al. First-generation versus second-generation drug-eluting stents in current clinical practise: updated evidence from a comprehensive meta-analysis of randomised clinical trials comparing 31 379 patients. Open Heart 2014;1:e000064. https://doi.org/10.1136/openhrt-2014-000064; PMID: 25332803.

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3